Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02167854 · ClinicalTrials.gov registry record · Phase 1

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
6
Study locations

NCT02167854: Completed Phase 1 study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02167854 is a Phase 1 study of Breast Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02167854, a Phase 1 study of Breast Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
6
Study locations

Study Summary

This is a Phase I study. The purpose of this study is to determine what is the best dose of the study drug BYL719 in combination with the study drug LJM716 and traztuzumab (Herceptin®). The study will test the safety of the combination of these three drugs, and to find out the effects, good and/or bad, that these three drugs have on the patient and breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG BYL719
  • DRUG TRASTUZUMAB
  • DRUG LJM716

Study Locations (6)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memoral Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Rockville Centre - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2014-06-16
Est. Completion 2021-07-07
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02167854

The ClinicalTrials.gov registry entry for NCT02167854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which BYL719 is the first listed.

NCT02167854 reports 6 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT02167854 about?

NCT02167854 is a clinical study titled "Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer". This is a Phase I study. The purpose of this study is to determine what is the best dose of the study drug BYL719 in combination with the study drug LJM716 and traztuzumab (Herceptin®). The study will test the safety of the combination of these three drugs, and to find out the effects, good and/or b...

What is the current status of trial NCT02167854?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2014-06-16. Estimated completion is 2021-07-07.

What conditions does trial NCT02167854 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02167854?

The interventions under investigation include: BYL719 (DRUG), TRASTUZUMAB (DRUG), LJM716 (DRUG).

Who is sponsoring clinical trial NCT02167854?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02167854 being conducted?

This trial has 6 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.